공수액백 시장 : 제품 유형, 소재 유형, 용량, 용도, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Empty IV Bags Market is projected to grow by USD 10.08 billion at a CAGR of 7.81% by 2032.

The empty IV bags market sits at the center of hospital medication delivery, parenteral nutrition, chemotherapy preparation, ambulatory infusion, emergency fluid management, and home infusion therapy. Demand is anchored by verified healthcare fundamentals, including rising surgical procedures, chronic disease management, aging populations, and the continued shift toward outpatient and home-based care documented by public health agencies and national health expenditure accounts.

Market dynamics are also shaped by product safety and compatibility requirements. Buyers increasingly evaluate sterile empty IV bags based on material composition, extractables and leachables performance, drug compatibility, port integrity, sterilization validation, particulate control, and compliance with medical device quality systems. As healthcare systems prioritize safer infusion workflows, suppliers that combine regulatory discipline with scalable sterile manufacturing are better positioned to support long-term procurement needs.

Transformative Shifts in the Empty IV Bags Landscape

The landscape is moving from commodity packaging toward high-assurance sterile fluid containers designed for medication safety, workflow efficiency, and environmental accountability. Hospitals, infusion centers, and compounding pharmacies are reassessing polyvinyl chloride-based formats where drug interaction risks, plasticizer concerns, or sustainability goals favor non-PVC alternatives such as polypropylene, polyethylene, and ethylene-vinyl acetate structures.

Another important shift is the expansion of centralized admixture services and outsourced sterile compounding. This trend increases the need for validated empty IV bags that support traceability, automated filling, tamper evidence, barcode labeling, closed-system workflows, and consistent performance under cold-chain, room-temperature, and light-protection requirements.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the empty IV bags value chain through demand planning, production scheduling, quality inspection, predictive maintenance, and supply-risk monitoring. AI-enabled visual inspection can support detection of seal defects, particulate contamination indicators, port irregularities, label defects, and packaging anomalies, while machine learning models can improve batch-yield analysis in sterile manufacturing environments.

The cumulative impact is strongest when AI is integrated into validated quality systems rather than used as a standalone tool. In procurement and hospital operations, predictive analytics can improve inventory levels for IV bags, reduce stockouts during seasonal surges, and align purchasing with procedure volumes, oncology cycles, parenteral nutrition demand, emergency preparedness, and drug shortage response requirements.

Key Regional Insights for Empty IV Bags

Asia-Pacific is supported by expanding hospital infrastructure, large patient populations, universal health coverage initiatives, and rising pharmaceutical manufacturing capacity, with China, India, Japan, South Korea, and Australia driving differentiated demand for sterile IV containers. North America remains a high-value region due to advanced hospital networks, regulated compounding practices, specialty infusion use, and strong adoption of medication safety technologies.

Europe emphasizes regulatory compliance, material safety, traceability, and sustainability under EU medical device and environmental frameworks, while Latin America is shaped by public hospital procurement, private healthcare expansion, and rising access to infusion therapies in Brazil and Mexico. The Middle East is investing in tertiary care, emergency preparedness, and local healthcare manufacturing, particularly in Gulf states, while Africa presents long-term opportunities tied to hospital capacity building, donor-supported healthcare programs, essential medicine delivery infrastructure, and improved access to sterile medical consumables.

Key Group Insights Across Global Healthcare Blocs

Across ASEAN, demand is supported by healthcare modernization, medical tourism hubs, expanding hospital capacity, and pharmaceutical packaging localization. The GCC is prioritizing hospital expansion, emergency readiness, and domestic medical supply resilience, creating opportunities for sterile IV bag suppliers that can meet international quality requirements and halal-sensitive procurement expectations where applicable.

The European Union creates a compliance-intensive environment shaped by EU MDR, sustainability policy, pharmacovigilance-linked traceability expectations, and centralized procurement discipline. BRICS economies combine high patient volumes with expanding local manufacturing and public healthcare investment, while the G7 favors premium, validated, and traceable products for acute care, oncology, nutrition therapy, and specialty infusion. NATO member countries add a preparedness dimension, where dependable infusion supply chains are relevant to military medicine, disaster response, mass-casualty planning, and strategic healthcare resilience.

Key Country Insights in Major Empty IV Bag Markets

The United States leads in high-acuity infusion demand, hospital purchasing scale, specialty pharmacy activity, and outsourced sterile compounding, while Canada emphasizes quality-assured supply, provincial procurement, and resilient access across geographically dispersed healthcare systems. Mexico and Brazil are influenced by public-private healthcare expansion, localized medical device distribution, and broader access to infusion-based treatments. In Europe, the United Kingdom, Germany, France, Italy, and Spain show sustained demand from hospital networks, oncology services, parenteral nutrition, ambulatory infusion, and regulated procurement systems, while Russia remains shaped by import substitution priorities and domestic healthcare supply policies.

In Asia-Pacific, China and India combine large patient bases with growing domestic production, making cost-effective sterile manufacturing, material consistency, and regulatory compliance decisive. Japan prioritizes high-quality, reliable infusion products for an aging population and advanced hospital care, while Australia relies on stringent quality standards, emergency preparedness, and resilient import channels. South Korea benefits from advanced healthcare infrastructure, pharmaceutical manufacturing capability, and strong adoption of precision hospital workflows.

Actionable Recommendations for Empty IV Bag Leaders

Industry leaders should prioritize validated sterile manufacturing, material innovation, and regulatory readiness. Non-PVC portfolios, robust extractables and leachables documentation, validated sterilization, particulate control, container-closure integrity, and drug compatibility data can strengthen supplier positioning with hospitals, compounding pharmacies, infusion providers, and pharmaceutical partners.

Vendors should also diversify supply chains, qualify secondary suppliers for films, ports, and closures, and use AI-supported demand planning to reduce shortage exposure. Strategic growth will depend on aligning product design with pharmacy automation, barcode traceability, closed-system preparation, sustainability requirements, and total cost of care rather than competing only on unit price.

Research Methodology

This executive summary is developed using a secondary-research-led methodology aligned with established market intelligence practices. The analysis synthesizes information from regulatory frameworks, public health agencies, medical device quality standards, healthcare expenditure databases, hospital procurement patterns, sterile compounding guidance, and published industry disclosures related to sterile infusion products.

Insights are triangulated across demand drivers, material trends, regional healthcare infrastructure, regulatory requirements, clinical workflow needs, and supply-chain indicators. The methodology emphasizes verified sources such as FDA quality system requirements, EU MDR principles, ISO sterilization and packaging standards, pharmacopeial particulate expectations, and country-level healthcare investment signals, while avoiding market sizing, market share, and forecasting claims.

Conclusion

The empty IV bags market is evolving from a price-driven consumable category into a strategic sterile delivery platform for modern healthcare. Demand is supported by infusion therapy utilization, hospital safety priorities, specialty medication workflows, outpatient care expansion, and increasing emphasis on validated supply resilience.

Suppliers that combine regulatory rigor, scalable sterile production, material science expertise, and digital quality capabilities will be well positioned to serve global healthcare systems. The most durable opportunities will emerge where clinical reliability, procurement efficiency, product compatibility, and sustainable innovation intersect.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Empty IV Bags Market, by Product Type

• 7.1. Single Chamber IV Bags
• 7.2. Multi-Chamber IV Bags

8. Empty IV Bags Market, by Material Type

• 8.1. Non-PVC
  • 8.1.1. EVA
  • 8.1.2. Polyethylene
• 8.2. PVC

9. Empty IV Bags Market, by Volume

• 9.1. Between 250 To 1000 mL
• 9.2. Above 1000 mL
• 9.3. Below 250 mL

10. Empty IV Bags Market, by Application

• 10.1. Dehydration Therapy
• 10.2. Drug Delivery
• 10.3. Nutritional Support
  • 10.3.1. Central Nutrition
  • 10.3.2. Peripheral Nutrition
• 10.4. Blood Transfusion Support
• 10.5. Chemotherapy Administration
• 10.6. Pain Management Infusion

11. Empty IV Bags Market, by End User

• 11.1. Clinics
• 11.2. Home Healthcare
• 11.3. Hospitals
  • 11.3.1. Public
  • 11.3.2. Private
• 11.4. Ambulatory Surgical Centers
• 11.5. Emergency Medical Services

12. Empty IV Bags Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Empty IV Bags Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Empty IV Bags Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Empty IV Bags Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Amcor plc
• 17.2. Angiplast Private Limited
• 17.3. B. Braun Melsungen AG
• 17.4. Baxter International Inc.
• 17.5. Becton Dickinson and Company
• 17.6. Eurolife Healthcare Pvt Ltd.
• 17.7. Fresenius Kabi AG
• 17.8. Grifols S.A.
• 17.9. Haemotronic SpA
• 17.10. ICU Medical Inc.
• 17.11. JW Life Science Corp.
• 17.12. Kraton Corporation
• 17.13. Maco Pharma
• 17.14. McGuff Medical Company Inc.
• 17.15. MedicoPack A/S
• 17.16. Mitra Industries Private Limited
• 17.17. Nipro Corporation
• 17.18. Otsuka Pharmaceutical Co. Ltd.
• 17.19. PiSA BioPharm
• 17.20. PolyCine GmbH
• 17.21. Renolit SE
• 17.22. Shandong Weigao Group Medical Polymer Co. Ltd.
• 17.23. Sichuan Kelun Pharmaceutical Co. Ltd.
• 17.24. Sippex IV Bag Solutions
• 17.25. SSY Group Limited
• 17.26. Technoflex SAS
• 17.27. Terumo Corporation
• 17.28. Vygon SA
• 17.29. West Pharmaceutical Services Inc.
• 17.30. Wipak Walsrode GmbH